Table 4.
Horizontal alveolar ridge augmentation with allogeneic bone block graft
| Study |
Year of publication |
Study design |
Outcome measures | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients |
ARW (mm) |
Site | Graft/N |
GH (months) |
Implant |
IH (months) |
Prosthetics |
OP (months) |
IS (%) |
PIMBL (mm) |
Histomorphometric measurements (%) |
GAW (mm)/ VRAA (%) |
BTC | ||||||
| Contar et al. [30] | 2009 | CS | 15 | NR | Maxil | FFA: 34 | 9 (8 - 11) | 51 | NR | NR | 24 - 35 | 100 | NR | NR | NR | GE: 1 | |||
| Nissan et al. [31] | 2011 | CS | 12 | ≤ 3 | Maxil mandible | FDA: 19 | 6 | 21 | 0 - 6 | Fixed prosthesis | 13 - 60 | 95.2 | No crestal bone loss beyond first thread | NR | 6 months |
GE: 4 Fistula: 1 |
|||
| 5 (SD 0.5) | |||||||||||||||||||
| Nissan et al. [32] | 2011 | CS | 24 | ≤ 3 | Mandible | FDA: 34 | 6 | 85 | 3 | Fixed prosthesis | 12 - 66 | 95.3 | NR | 6 months | 6 months | NR | |||
| NBF | RG | CT | 5.6 (SD 1)/5 | ||||||||||||||||
| 40 (SD 28) | 29 (SD 24) | 27 (SD 21) | |||||||||||||||||
| Orsini et al. [33] | 2011 | CS | 10 | 1.5 - 2.8 | Maxil | FFA: 10 | 5 | 14 | 5 | Single crowns | 24 | 100 | NR | 6 months | 5 months | TGL: 1 | |||
| NBF | 58 (SD 25) | 4.6 (SD 0.5) | |||||||||||||||||
| Acocella et al. [34] | 2012 | CS | 16 | 2 - 4 | Maxil | FFA: 18 | 4 - 9 | 34 | 4 | Fixed prosthesis | 18 - 30 | 100 | NR | Non-vital bone: 62 (SD 12) | 4 - 9 months | GE: 1 | |||
|
4.1 (SD 0.8)/ 11.5 (0 - 30) | |||||||||||||||||||
| Nissen et al. [35] | 2012 | CS | 40 | ≤ 3 | Maxil | FDA: 60 | 6 | 83 | 3 | Fixed prosthesis | 14 - 82 | 98.8 | NR | 6 months | NR | DH: 16 | |||
| NBF | RG | CT | |||||||||||||||||
| 33 (SD 18) | 26 (SD 17) | 41 (SD 2) | |||||||||||||||||
| Novell et al. [36] | 2012 | CS | 15 | NR | Maxil mandible | FDA: 36 | 4 - 6 | 53 | 4 - 6 | NR | 12 - 60 | 100 | NR | NR | NR |
GE: 1 FG: 1 |
|||
| Chiapasco et al. [37] | 2015 | CS | 19 | ≤ 3 | Maxil mandible | FFA: NR | 5 - 7 | 117 | 5 - 6 | NR | 20 - 32 | 90.2 | 12 months | 24 months | NR | NR |
DH: 14 PGL: 5 TGL: 2 |
||
| 1.6 (SD 1.6) | 1.9 (SD 1.4) | ||||||||||||||||||
| Aslan et al. [38] | 2016 | CS | 11 | < 5 | Maxil mandible | DFDA: 12 | 5 | 32 | 3 | Fixed prosthesis | 24 | 100 | NR | 5 months | 5 months | None | |||
| NBF | RG | CT | 1.7 (SD 0.1)/5.4 | ||||||||||||||||
| 40 (SD 25) | 40 (SD 21) | 19 (SD 15) | |||||||||||||||||
| Deluiz et al. [39] | 2016 | CS | 8 | NR | Maxil | FFA: NR | 4 - 6 | 268 | 4 | Fixed prosthesis | 12 | 94 | NR | NR | NR |
DH: 5 PGL: 4 TGL: 3 |
|||
| Silva et al. [40] | 2017 | CS | 20 | ≤ 6 | Mandible | FFA: 50 | 6 | 50 | 6 | Single-crown | 20 - 42 | 96 | NR | 6 months | 12 months | GE: 6 | |||
| NBF | RG | CT | 4 (SD 0.7)/41 | ||||||||||||||||
| 32 (SD 1) | 15 (SD 0) | 54 (SD 1) | |||||||||||||||||
| Chaushu et al. [41] | 2019 | CS | 14 | NR | Mandible | NR: 24 | 6 | 26 | 3 | Mostly fixed prosthesis | 12 - 54 | 100 | No crestal bone loss beyond first thread | 6 months | 5 (SD 0.5) |
GE:6 TGL: 2 PGL: 6 |
|||
| NBF | RG | CT | |||||||||||||||||
| 42 | 17 | 41 | |||||||||||||||||
ARW = alveolar ridge width; BTC = biological and technical complications; CS = case series; CT = connective tissue; DFDA = demineralized freeze-dried bone allograft; DH = dehiscence; FDA = freeze-dried bone allograft; FFA = fresh-frozen bone allograft; FG = fracture graft; GAW = gain in alveolar ridge width; GE = graft exposure; GH = graft heling; IH = Implant healing; IS = implant survival; N = number; NBF = new bone formation; NR = not reported; OP = observation period after functional implant loading; PGL = partial graft loss; RG = residual graft; TGL = total graft loss; VRAA = volumetric reduction of the augmented area; SD = standard deviation.